Condition: Hepatocellular Carcinoma · Sponsor: Beijing Shenogen Biomedical Co., Ltd
A study to evaluate the efficacy and safety of icaritin versus huachansu in the first-line treatment of unresectable hepatocellular carcinoma with poor conditions and biomarker enrichment.
This description comes directly from the study's public registry record.
Jihui Hao, MD · 022-23340123 · haojihui@tjmuch.com
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | Recruiting |
| Chifeng Municipal Hospital | Chifeng, Mongolia, China | Recruiting |
| Tianjin Medical University Cancer Institute & Hospital | Tianjin, Tianjin Municipality, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05594927